1 Introduction Glioblastoma (GBM) is the most lethal primary brain tumor, with a median survival of 12–15 months despite standard therapy (1). One major factor underlying this poor prognosis is the extreme inter- and intra-tumor molecular heterogeneity of GBM (2). GBM tumors contain diverse cellular subpopulations; for example, a small fraction of glioma stem-like cells is thought to drive therapy resistance and recurrence (3).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Youhui
Contact Youhui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack